SCHEMBL10352269

SCHEMBL10352269

CC(=O)/C=C/c1ccccc1OCc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.74
PTGER2 P43116 6/20 0.74
PTGER3 P43115 5/20 0.74
PTGER1 P34995 4/20 0.74
CCNB2 O95067 1/20 0.63
CDK1 P06493 1/20 0.63
CDK4 P11802 1/20 0.63
CCNB1 P14635 1/20 0.63
CCND1 P24385 1/20 0.63
CCNB3 Q8WWL7 1/20 0.63
KDM4E B2RXH2 2/20 0.62
HDAC8 Q9BY41 1/20 0.56
BRD4 O60885 1/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
POLB P06746 1/20 0.52
PKM P14618 1/20 0.52
BLM P54132 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAPT P10636 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10352270 1.00 PTGER4 (0.74) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL8323198 0.88 PTGER4 (0.94) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL8323200 0.88 PTGER4 (0.94) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL19651747 0.85 PTGER4 (0.70) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL7770104 0.85 PTGER4 (0.70) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL27919653 0.85 PTGER4 (0.74) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL10870470 0.85 PTGER1 (0.54) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL10870465 0.85 PTGER1 (0.54) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL27746895 0.84 PTGER1 (0.72) PTGER4PTGER2PTGER3PTGER1CCNB2
SCHEMBL27746894 0.84 PTGER1 (0.72) PTGER4PTGER2PTGER3PTGER1CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS BONFANTI JEAN-FRANCOIS 2009-09-03 US disclosed
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS BONFANTI JEAN-FRANCOIS 2009-09-03 US disclosed
WO-2007026024-A2 BENZODIAZEPINES AS HCV INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-03-08 WO disclosed
EP-0177222-B1 CYCLOHEXANE-1,3-DIONE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PROCESSES FOR PREPARING THEM, AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS ICI AUSTRALIA LIMITED (AU) 1990-06-27 EP disclosed
US-4604128-A Herbicidal cyclohexane-1,3-dione derivatives ICI AUSTRALIA LIMITED (AU) 1986-08-05 US disclosed
EP-0177222-A1 Cyclohexane-1,3-dione derivatives, compositions containing them, processes for preparing them, and their use as herbicides and plant growth regulators ICI AUSTRALIA LIMITED (AU) 1986-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS GABRA5, GABRA4, GABRA3 PTGER4 2366/4885PTGER2 2989/4885PTGER3 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.